Zakerska-Banaszak Oliwia, Łykowska-Szuber Liliana, Walczak Michał, Żuraszek Joanna, Zielińska Aleksandra, Skrzypczak-Zielińska Marzena
Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland.
Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland.
Toxics. 2022 Mar 22;10(4):151. doi: 10.3390/toxics10040151.
The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications. Since then, they have been used routinely to maintain remission of Crohn's disease (CD) and ulcerative colitis (UC). The cytotoxic properties of thiopurines and the numerous adverse effects of the treatment are controversial. However, the research subject of their pharmacology, therapy monitoring, and the search for predictive markers are still very relevant. In this article, we provide an overview of the current knowledge and findings in the field of thiopurines in IBD, focusing on the aspect of their cytotoxicity. Due to thiopurines' benefits in IBD therapy, it is expected that they will still constitute an essential part of the CD and UC treatment algorithm. More studies are still required on the modulation of the action of thiopurines in combination therapy and their interaction with the gut microbiota.
硫嘌呤类药物在炎症性肠病（IBD）中的有效性在半个多世纪前就得到了证实。事实证明，这些药物可能是重要的免疫调节药物。从那时起，它们就被常规用于维持克罗恩病（CD）和溃疡性结肠炎（UC）的缓解。硫嘌呤的细胞毒性特性以及治疗的众多不良反应存在争议。然而，它们的药理学、治疗监测以及寻找预测标志物的研究课题仍然非常重要。在本文中，我们概述了IBD领域中硫嘌呤类药物的当前知识和研究结果，重点关注其细胞毒性方面。由于硫嘌呤类药物在IBD治疗中的益处，预计它们仍将是CD和UC治疗方案的重要组成部分。关于硫嘌呤类药物在联合治疗中的作用调节及其与肠道微生物群的相互作用，仍需要更多的研究。
